Market closedNon-fractional
Scholar Rock/SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Ticker
SRRK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
150
Website
scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$754M
Market cap
-
P/E ratio
-$2.30
EPS
0.94
Beta
-
Dividend rate
Price and volume
Market cap
$754M
Beta
0.94
Financial strength
Current ratio
6.584
Quick ratio
6.387
Long term debt to equity
25.718
Total debt to equity
32.897
Interest coverage (TTM)
-29.11%
Management effectiveness
Return on assets (TTM)
-40.64%
Return on equity (TTM)
-89.09%
Valuation
Price to book
4.11
Price to tangible book (TTM)
4.11
Price to free cash flow (TTM)
-4.957
Growth
Earnings per share change (TTM)
-2.84%
3-year earnings per share growth (CAGR)
-8.42%
What the Analysts think about Scholar Rock
Analyst Ratings
Majority rating from 9 analysts.
Scholar Rock Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$57M
23.21%
Profit margin
0.00%
NaN%
Scholar Rock Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.53
-$0.50
-$0.59
-
Expected
-$0.56
-$0.52
-$0.49
-$0.51
-$0.61
Surprise
-15.36%
1.75%
2.56%
15.86%
-
Scholar Rock News
AllArticlesVideos
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Business Wire·1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $754M as of July 27, 2024.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of July 27, 2024.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Scholar Rock stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.